Advertisement
Screener

GENELUX CORPORATION (GNLX) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum

1.7 / 5 stars · 8/23 Roast Me

GENELUX CORPORATION Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum

GENELUX CORPORATION (GNLX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum of 94.60% for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-29.

Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum · last filed 2024-03-29

  • GENELUX CORPORATION share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for fiscal 2022 was 94.60%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum 12 month
2022-12-3194.60%
10-K · filed 2024-03-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
BICYCLE THERAPEUTICS PLC (BCYC)$0.112B-1.56
Equillium, Inc. (EQ)United States$0.109B-11.27
Quantum Cyber N.V. (QUCY)$0.113B
Immuneering Corp (IMRX)United States$0.113B-12.51
Biomea Fusion, Inc. (BMEA)United States$0.107B-3.30
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
ProMIS Neurosciences Inc. (PMN)$0.102B
OnKure Therapeutics, Inc. (OKUR)United States$0.119B-3.13
Coya Therapeutics, Inc. (COYA)United States$0.121B-6.35
CUMBERLAND PHARMACEUTICALS INC (CPIX)United States$0.121B-8.95